Article
Nondisruptive p53 mutations are associated with shorter survival in patients with advanced non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Sept 2014
Molina-Vila Miguel A, Bertran-Alamillo Jordi, Gascó Amaya, Mayo-de-las-Casas Clara, Sánchez-Ronco María, Pujantell-Pastor Laia, Bonanno Laura, Favaretto Adolfo G, Cardona Andrés F, Vergnenègre Alain, Majem Margarita, Massuti Bartomeu, Morán Teresa, Carcereny Enric, Viteri Santiago, Rosell Rafael
Abstract excerpt
PURPOSE: TP53 mutations in early-stage non-small cell lung cancer (NSCLC) may be associated with worse survival but their prognostic role in advanced NSCLC is controversial. In addition, it remains unclear whether mutated patients represent a clinically homogeneous group. EXPERIMENTAL DESIGN: We retrospectively examined TP53 mutations and outcome in a training cohort of 318 patients with stage IIIB-IV NSCLC: 125...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
